| DC65513 |
HYNIC-FAPI-04
Featured
|
HYNIC-FAPI-04 is a useful ligand for making [99mTc]Tc-HYNIC-FAPI-04. In vitro experiments, the results indicated that [99mTc]Tc-HYNIC-FAPI-04 showed binding properties, and inhibited the migration of tumor cells. The [99mTc]Tc-HYNIC-FAPI will be a promising SPECT/CT imaging probe. |
|
| DC65514 |
NOTA-FAPI-46
Featured
|
NOTA-FAPI-46 is an analogue of FAPI-46 (MedKoo Cat#207189). NOTA-FAPI-46 is useful in the diagnosis or treatment of a disease characterized by overexpression of fibroblast activation protein (FAP). NOTA-FAPI-46 can be used as a PET tracer for detection of diseases or disorders related to fibroblast activation protein. |
|
| DC65515 |
HYNIC-PSMA
Featured
|
HYNIC-PSMA is a PSMA based ligand, which can bind radio-active metal ion and used as a tumor-imaging agent in prostate cancer. 99mTc-HYNIC-PSMA is a novel technetium-99m-labeled small-molecule inhibitor of prostate-specific membrane antigen (PSMA) for detection of prostate cancer. 99mTc-HYNIC-PSMA showed high tracer uptake (with a tumor-to-background ratio of 9.42 ± 2.62) in the malignant lesions of PCa patients, making it a promising radiopharmaceutical imaging method for site-specific management of PCa. |
|
| DC65516 |
PSMA-BCH
Featured
|
PSMA-BCH also known as NOTA-PSMA, is a PSMA- NOTA-conjugated precursor. 68Ga-PSMA-BCH can be used for prostate cancer imaging. Al18F-PSMA-BCH can be used for prostate cancer imaging as a novel 18F PET radiotracer. 64Cu-PSMA-BCH is a new radiotracer for delayed PET imaging of prostate cancer. 64Cu-PSMA-BCH was PSMA specific and showed high stability in vivo with lower uptake in liver than 64Cu-PSMA-617. Biodistribution in mice and PCa patients showed similar profile compared with other PSMA ligands and it was safe with moderate effective dosimetry. |
|
| DC65517 |
PSMA-I&T
Featured
|
PSMA-I&T is a PSMA-based radioligand. [177Lu]Lu-PSMA I&T can be uused for potential treatment of metastatic castration-resistant prostate cancer. 67 Ga-PSMA I&T can be used for Radioguided Surgery of Lymph Node Metastases With Biochemical Recurrence of Prostate Cancer |
|
| DC89101 |
C12-4 (C12-494,Lipid A-4)
Featured
|
C12-4 (C12-494,Lipid A-4) is a branched-chain ionizable cationic lipidoid that has been used in the formation of lipid nanoparticles (LNPs) for the delivery of mRNA. LNPs containing lipid A4 and encapsulating an mRNA reporter accumulate in the uterus, placenta, and ovaries, as well as to the spleen and liver, in pregnant mouse dams unlike LNPs containing the branched-chain ionizable cationic lipidoid C12-200, which primarily accumulate in the liver. Intravenous administration of LNPs containing lipid A4 and encapsulating mRNA encoding VEGF increase placental VEGFR1 levels and mean fetal blood vessel area without inducing liver damage in pregnant mouse dams. |
|
| DC60484 |
Clovibactin
Featured
|
Clovibactin is an antibiotic isolated from uncultured soil bacteria. Clovibactin efficiently kills drug-resistant Gram-positive bacterial pathogens without detectable resistance. Clovibactin blocks cell wall synthesis by targeting pyrophosphate of multiple essential peptidoglycan precursors. |
|
| DC65518 |
STC15
Featured
|
STC-15 is a groundbreaking, orally bioavailable, highly selective inhibitor of METTL3, an RNA methyltransferase enzyme that plays a critical role in regulating gene expression through N6-methyladenosine (m6A) modification of RNA. METTL3 is implicated in the pathogenesis of various cancers, including acute myeloid leukemia (AML) and solid tumors. STC-15 represents the first molecule specifically targeting an RNA methyltransferase enzyme to enter clinical development, marking a significant milestone in the field of epitranscriptomics and cancer therapy. |
|
| DC65519 |
TNG462
Featured
|
Discovery of TNG462, a highly potent and selective MTA-cooperative PRMT5 inhibitor that is synthetic lethal for MTAP deleted cancers |
|
| DC65520 |
TNG908
Featured
|
TNG908 is a MTAP-cooperative PRMT5 inhibitor that can pass through the blood-brain barrier. TNG908 is 15 times more selective for MTAP null cell lines than MTAPWT cell lines, and can be used in cancer research. |
|
| DC65521 |
PTC-258 2HCl
Featured
|
PTC-258 2HCl is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model. |
|
| DC65522 |
Nico-52
Featured
|
|
|
| DC65523 |
JNT-517
Featured
|
JNT-517 is a small-molecule inhibitor of the phenylalanine transporter SLC6A19 that has the potential to be a first-in-class oral therapy used to treat any person with PKU, regardless of age or genotype. JNT-517 acts at a novel, cryptic allosteric site to block kidney reabsorption of Phe and offers a promising new approach to reduce blood Phe levels. The FDA has granted JNT-517 Rare Pediatric Disease Designation. |
|
| DC65524 |
CHK-336
Featured
|
CHK-336 (Example 1) is an orally active LDHA inhibitor (IC50<1 nM) that inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria. |
|
| DC65525 |
Resigratinib (KIN-3248)
Featured
|
Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations |
|
| DC72906 |
BCPA
Featured
|
BCPA is a Pin1 regulator without cytotoxicity. BCPA attenuates the reduction of Pin1 protein to inhibit receptor activator of RANKL-induced osteoclastogenesis. BCPA regulates osteoclast activation, used to osteoporosis research. |
|
| DC72911 |
CHBO4
Featured
|
CHBO4 is a potent, reversible, competitive, and selective hMAO-B inhibitor with an IC50 value of 0.031 μM in CHBO subseries and an Ki value of 0.010 ± 0.005 μM. CHBO4 reduce cell damage by scavenging intracellular reactive oxygen species (ROS). CHBO4 can be used for Parkinson's Disease (PD) research. |
|
| DC72912 |
IK-930
Featured
|
IK930 (compound I-32) is a potent and orally active TEAD inhibitor with an EC50 value of <0.1 µM. |
|
| DC65529 |
n10-methylfolic acid
Featured
|
Methopterin has the activation and bone resorption function of murine osteoclasts. |
|
| DC65530 |
niacinamide ascorbate
Featured
|
Nicotinamide ascorbate is a bioactive chemical. |
|
| DC65531 |
Anticancer agent 118
Featured
|
Anticancer agent 118, a N‑acylated ciprofloxacin derivative, has anti-bacterial and anticancer activities. |
|
| DC65532 |
MtUng-IN-1
Featured
|
MtUng-IN-1 (Compound 18a) is a Uracil DNA glycosylase of Mycobacterium (MtUng) inhibitor (IC50: 300 μM). MtUng-IN-1 can be used for research of cancers and infectious diseases. |
|
| DC60488 |
CL1H6
Featured
|
CL1H6 is an ionizable lipid designed for advanced nucleic acid delivery, and its lipid nanoparticle formulation, CL1H6-LNP, demonstrates exceptional efficiency in delivering both siRNA and mRNA into NK-92 cells. This innovative system enables precise and effective intracellular delivery, making it a valuable tool for enhancing therapeutic and research applications in natural killer cell biology. |
|
| DC65560 |
GalNAc-L96 free base
Featured
|
GalNAc-L96 free base, the G-rich oligonucleotides carrying the longer GalNAc linker that can be used for delivery of nucleic acid drugs. |
|
| DC65559 |
GalNAc-L96 Phosphoramidite
Featured
|
|
|
| DC65561 |
GalNac-L96 analog
Featured
|
GalNAc-L96 analog is an intermediate in the synthesis of the asialoglycoprotein receptor (ASGPR) ligand GalNAc-L96. |
|
| DC65562 |
GalNAc-NAG-25 Phosphoramidite
Featured
|
|
|
| DC65563 |
GalNAc-L96-CPG
Featured
|
|
|
| DC65564 |
GalNAc-L96-PS
Featured
|
|
|
| DC65565 |
GalNac-L96
Featured
|
GalNac-L96, the G-rich oligonucleotides carrying the longer GalNAc linker that can be used for delivery of nucleic acid drugs[1]. |
|
